Topiramate (Epilepsy)

Hypospadias

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S7662
R22678		 Tomson (Topiramate), 2018 Hypospadias at least 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 2.77 [0.33;23.14] C 1/152   6/2,514 7 152
ref
S6061
R15761		 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 Hypospadias/genitourinary tract defects 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 3.96 [0.46;34.03] C 1/28   6/647 7 28
ref
Total 2 studies 3.30 [0.73;14.97] 14 180
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Tomson (Topiramate), 2018Tomson, 2018 1 2.77[0.33; 23.14]715251%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006Morrow, 2006 2 3.96[0.46; 34.03]72849%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 3.30[0.73; 14.97]141800.910.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Topiramate; 2: Topiramate) (Controls exposed to Lamotrigine, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 3.30[0.73; 14.97]141800%NATomson (Topiramate), 2018 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 2 case control studiescase control studies 0 Type of controls exposed to other treatment, sickexposed to other treatment, sick 3.30[0.73; 14.97]141800%NATomson (Topiramate), 2018 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 2 Tags Adjustment   - No  - No 3.30[0.73; 14.97]141800%NATomson (Topiramate), 2018 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 2 All studiesAll studies 3.30[0.73; 14.97]141800%NATomson (Topiramate), 2018 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 20.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls exposed to other treatment, sick controlsexposed to other treatment, sick controls 3.30[0.73; 14.97]141800%NATomson (Topiramate), 2018 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 20.510.01.0